CA3233673A1 - Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity - Google Patents
Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity Download PDFInfo
- Publication number
- CA3233673A1 CA3233673A1 CA3233673A CA3233673A CA3233673A1 CA 3233673 A1 CA3233673 A1 CA 3233673A1 CA 3233673 A CA3233673 A CA 3233673A CA 3233673 A CA3233673 A CA 3233673A CA 3233673 A1 CA3233673 A1 CA 3233673A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- occurrence
- mixture
- mmol
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/121548 | 2021-09-29 | ||
| CN2021121548 | 2021-09-29 | ||
| PCT/US2022/077120 WO2023056264A1 (en) | 2021-09-29 | 2022-09-27 | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3233673A1 true CA3233673A1 (en) | 2023-04-06 |
Family
ID=84329267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3233673A Pending CA3233673A1 (en) | 2021-09-29 | 2022-09-27 | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240400561A1 (https=) |
| EP (1) | EP4408843A1 (https=) |
| JP (1) | JP2024538602A (https=) |
| KR (1) | KR20240089127A (https=) |
| CN (1) | CN118251393A (https=) |
| AU (1) | AU2022356377A1 (https=) |
| CA (1) | CA3233673A1 (https=) |
| IL (1) | IL311784A (https=) |
| MX (1) | MX2024003948A (https=) |
| WO (1) | WO2023056264A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11465992B2 (en) * | 2017-07-07 | 2022-10-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| US11370776B2 (en) * | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| MX2020001776A (es) * | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| US11542255B2 (en) * | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| EP3668861A1 (en) * | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| KR20200087759A (ko) * | 2017-11-09 | 2020-07-21 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| GB201902327D0 (en) * | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
-
2022
- 2022-09-27 JP JP2024519269A patent/JP2024538602A/ja active Pending
- 2022-09-27 KR KR1020247014041A patent/KR20240089127A/ko active Pending
- 2022-09-27 WO PCT/US2022/077120 patent/WO2023056264A1/en not_active Ceased
- 2022-09-27 MX MX2024003948A patent/MX2024003948A/es unknown
- 2022-09-27 CN CN202280075492.3A patent/CN118251393A/zh active Pending
- 2022-09-27 AU AU2022356377A patent/AU2022356377A1/en active Pending
- 2022-09-27 IL IL311784A patent/IL311784A/en unknown
- 2022-09-27 CA CA3233673A patent/CA3233673A1/en active Pending
- 2022-09-27 EP EP22801649.9A patent/EP4408843A1/en active Pending
- 2022-09-27 US US18/696,901 patent/US20240400561A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL311784A (en) | 2024-05-01 |
| AU2022356377A1 (en) | 2024-04-11 |
| WO2023056264A1 (en) | 2023-04-06 |
| CN118251393A (zh) | 2024-06-25 |
| EP4408843A1 (en) | 2024-08-07 |
| JP2024538602A (ja) | 2024-10-23 |
| US20240400561A1 (en) | 2024-12-05 |
| KR20240089127A (ko) | 2024-06-20 |
| MX2024003948A (es) | 2024-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7508584B2 (ja) | ＰＩ３Ｋα阻害剤およびそれらの使用 | |
| CA3229539A1 (en) | Inhibitors of nlrp3 | |
| CA3016182C (en) | Substituted indole mcl-1 inhibitors | |
| CA2930414C (en) | Tetrahydroquinoline compositions as bet bromodomain inhibitors | |
| CA2979391C (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
| ES2450568T3 (es) | Compuestos espiero de amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso médico | |
| CA3047336A1 (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
| EP4129996A1 (en) | Novel aminopyrimidine egfr inhibitor | |
| JP2015025014A (ja) | キナーゼ阻害剤として有用な２−アミノピリジン誘導体 | |
| CA3033461A1 (en) | Heterocyclic compounds as inhibitors of gcn2 | |
| WO2016004136A1 (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
| CA2731432A1 (en) | Tri-cyclic pyrazolopyridine kinase inhibitors | |
| CA2916468A1 (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
| MX2011011653A (es) | Pirazolopiridinas. | |
| CA2654410A1 (en) | Inhibitors of janus kinases | |
| CA3095568A1 (en) | Heterocyclic compound | |
| CN119487006A (zh) | 作为pge2受体拮抗剂的酰胺化合物 | |
| CA3074059A1 (en) | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | |
| CA3233673A1 (en) | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | |
| IL298397A (en) | Competitive and noncompetitive inhibitors of the muscarinic acetylcholine receptor m5 | |
| US12338255B2 (en) | Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | |
| HK40107097A (zh) | 作为白介素-1活性抑制剂的新型经取代的磺酰脲化合物 | |
| EA052733B1 (ru) | Ингибиторы nlrp3 | |
| JP2025502100A (ja) | 疾患の治療のためのｇｌｕｔ９の複素環式阻害剤 | |
| CN106065018A (zh) | 取代的吲哚化合物及其使用方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250826 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250826 |